Tag Archives: ICT

Computers

EU teachers need more IT training, report says

Leave a comment

The latest European Union survey of ICT in schools has found that 20 percent of secondary students have never or almost never used a computer in school.

Speaking at the presentation of the survey on Friday, the E.U.’s Digital Agenda Commissioner Neelie Kroes said there was a very real need for more IT skills training for teachers. “ICT skills and training must be available to all students and teachers, not just a lucky few,” she said.

Teacher training in ICTs is rarely compulsory, so most teachers are forced to use their spare time to improve ICT skills.

The survey, which takes place every five years, found that although computer numbers have doubled since 2006 — largely thanks to laptops, tablets and netbooks, which are replacing desktop computers in many schools — there are still vast differences between Scandinavian and Nordic countries (the best equipment) and countries such as Poland, Romania, Italy, Greece, Hungary and Slovakia.

To read this article in full or to leave a comment, please click here

From: http://www.pcworld.com/article/2035766/eu-teachers-need-more-it-training-report-says.html#tk.rss_all

Science & Technology

ICT plays an increasing part in criminal activities

Leave a comment

The influence of ICT on traditional crimes such as burglary, robbery, intimidation and fraud is on the rise. Researchers from the University of Twente examined a large number of crimes in the east of the Netherlands on behalf of and in collaboration with PAC – the police cybercrime programme – and the five regional police forces which now form the East Netherlands unit. They looked into 136 burglaries, 140 commercial burglaries, 259 instances of threatening behaviour and 274 cases of fraud. The fraud cases in particular had a strong digital component. …read more

Source: FULL ARTICLE at Phys.org

Business, Finance, Occupation & Industry

Obama Trade Official to Keynote Forum on Africa, Near East, South Asia

March 25, 2013, WASHINGTON – Under Secretary of Commerce for International Trade Francisco Sánchez will offer the keynote address at ACCESS 2013, an international trade forum showcasing growing business opportunities in the Africa, Near East and South Asia (ANESA) region in La Jolla, Calif., May 1-2, 2013.

“The ANESA region is showing unprecedented growth, which represents a wealth of opportunities for U.S. businesses. ACCESS 2013 gathers together specialists from both the public and private sector to help you gain access into the region and give you the tools to be successful,” said Sánchez.

During the two-day gathering, participants will also hear from Ambassador Charles Ford, Deputy Director General of the U.S. and Foreign Commercial Service (Commercial Service), and senior trade specialists from the Commercial Service and State Department Economic sections from U.S. embassies in the ANESA region.

The forum offers California companies a unique chance to tap into the growing business opportunities of the ANESA region, which includes India, Israel, Saudi Arabia, the United Arab Emirates, Egypt, Nigeria, and South Africa. These seven markets present numerous opportunities for U.S. exports of technology, equipment and more, and are projected to purchase more than $100 billion worth of American-made goods this year.

ACCESS 2013 will include a networking reception, multiple sessions on market entry strategies, financing, legal and regulatory issues and logistics. Focused industry sessions will include aerospace and defense, ICT, healthcare, water and energy, security and transportation, and services such as education and franchising. Panelists will include Commercial Service and other U.S. Embassy officials, as well as private sector industry and regional experts.

The event is a public-private collaboration of the Commercial Service, San Diego State University’s Center for International Business Education and Research (CIBER), and the San Diego and Imperial Counties District Export Council. Markets featured at the conference will be: Algeria, Egypt, Ethiopia, Ghana, India, Iraq, Israel, Ivory Coast, Jordan, Kenya, Kuwait, Lebanon, Libya, Morocco, Nigeria, Oman, Pakistan, Qatar, Saudi Arabia, South Africa, and the United Arab Emirates.

Individuals who wish to attend can register at the US Export.gov website by clicking on the San Diego link. Registration is $495 if completed before March 31, 2013. Afterward that date, the fee is $595.

Total U.S. exports to the ANESA region totaled $80 billion in 2012. Top U.S. exports to this region were: vehicles and parts ($14.0 billion); aircraft and parts ($12.6 billion); machinery ($11.2 billion); electric machinery ($7.5 billion); precious stones and metals ($7.3 billion); optic and medical instruments ($2.9 billion); mineral fuel ($2.4 billion); special classification provisions ($1.9 billion); oil seeds and grains ($1.7 billion); arms and ammunition ($1.5 billion).

Press Contact:
PRL US Commercial Service Public Relations Contact
US Commercial Service
441 Santaluz Path, Austin, TX 78732 US
prl_uscommercialservice@vos-us.com
http://www.export.gov/sandiego

Business, Finance, Occupation & Industry

ImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5th

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5th

LOS ANGELES–(BUSINESS WIRE)– ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the BioCentury and Thomson Reuters 20th Annual Future Leaders in the Biotech Industry conference on Friday, April 5, 2013 at 11:00 am ET at the Millennium Broadway Hotel, New York City.

To access the live audio webcast of the Future Leaders presentation, please log on through a link located in the Investors section of ImmunoCellular’s website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.348.0010
jane@jmgcomm.com

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:

The article ImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5th originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

TELUS Selects Fujitsu for 100G Inter-City Regional Network Deployments

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

TELUS Selects Fujitsu for 100G Inter-City Regional Network Deployments

RICHARDSON, Texas–(BUSINESS WIRE)– Fujitsu, a leading provider of business, information technology, and communications solutions, announced today that TELUS has selected Fujitsu to help bring 100G performance to the service provider’s network. By utilizing the Fujitsu 100G solution on the Fujitsu FLASHWAVE® 9500 Packet Optical Networking Platform (Packet ONP), TELUS will be able to meet the bandwidth requirements for high-speed data services, Internet video services, and smart phones, while ensuring a better cost per unit and a lasting technology foundation for their evolving packet-centric regional and national network.

“Our partnership with Fujitsu enables us to continue providing the reach, bandwidth and reliability that our customers require,” said Zouheir Mansourati, Vice President, TELUS Fixed Network Planning & Engineering. “Additionally, by utilizing the FLASHWAVE 9500 Packet ONP for 100G connectivity, TELUS can deliver a high level of service while achieving more efficient regional network utilization, better cost per gigabit of IP traffic, and lower operating cost. Our customers know that TELUS will always support their communications needs with the most advanced and reliable technologies available.”

The Fujitsu 100G solution is designed to meet the demand for bandwidth growth in core networks driven by high speed data services, internet video services, and the wide adoption of bandwidth intensive smart phones. The Fujitsu 100G solution can be cost-effectively deployed to expand network capacity by a factor of 10, eliminating the need for expensive, overlay networks.

“Carrier networks are facing tremendous increases in bandwidth transported,” said Rod Naphan, Senior Vice President of Product and Strategic Planning for Fujitsu Network Communications. “At the same time, these networks are under immense pressure to lower their cost per bit transported. Fujitsu’s 100G technology can help TELUS achieve better network utilization, higher spectral efficiencies and lower overall operating costs.”

About Fujitsu

Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Over 170,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 4.5 trillion yen (US$54 billion) for the fiscal year ended March 31, 2012. For more information, please see: http://www.fujitsu.com.

About Fujitsu Network Communications Inc.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Demand Media Takes Domain Services Business to Dublin

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Demand Media Takes Domain Services Business to Dublin

Company Names David Ryan as General Manager to Oversee Efforts for Historic New TLD Launch

SANTA MONICA, Calif.–(BUSINESS WIRE)– Demand Media® (NYS: DMD) , a leading digital media and domain services company, today announced the opening of what will be its largest international office in Dublin, Ireland. With an international presence that currently includes offices in Toronto, Buenos Aires and London, Demand Media‘s Dublin office will serve as the international headquarters for the company’s domain services business. The team in the new location is focused on preparing for the historic change about to take place on the Internet, as thousands of new domain names, called new Top Level Domains (TLDs), come to market later this year. To lead the new Dublin operation during this pivotal time in the domain business, the company has hired David Ryan as General Manager, most recently with Fortune 500 Company Electronic Arts.

Located in Center City Dublin, the office models that of a technology start-up, and the company is seeking talent with experience across all functions, including product engineering, sales & marketing, IT, finance, operations and customer support, and expects to employ between 20 and 40 people within the next year. The Demand Media team will be based at One Clarendon Row, located next to the historic Gaiety Theatre and St. Stephen’s Green. As a part of the company’s expansion, Demand Media partnered with the Irish Department of Jobs, Enterprise and Innovation through IDA Ireland, the country’s premiere investment promotion agency, to set up and develop the new location.

“We are excited to expand our business into the thriving tech scene of Dublin,” commented Dave Panos, executive vice president of emerging markets for Demand Media. “At such an exhilarating time in the domain services industry with the upcoming launch of new TLDs, we are eager to recruit creative and high-energy professionals who are up to the challenge of taking the lead in the changing Internet landscape.”

The Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, said, “ICT is a major part of the Government’s plans for jobs and growth, and in the time since we took office over 11,000 additional people are employed in this sector. Today’s announcement that this leading US company is opening its largest international office in Dublin is a further boost for the sector. Through continued implementation of the Action Plan for Jobs I am determined to build on this and support the jobs growth we need.”

…read more
Source: FULL ARTICLE at DailyFinance

Science & Technology

Researcher finds intuition prevails in innovative decision making

Leave a comment

Decisions concerning innovations in the early stages of product development arise mostly from intuition. Olli Hyppänen has studied development work in strongly innovative ICT companies in his doctoral dissertation for the Department of Industrial Engineering and Management in Aalto University. He shows that innovative decision making is often remarkably intuitive. …read more
Source: FULL ARTICLE at Phys.org

Business, Finance, Occupation & Industry

ImmunoCellular Therapeutics to Present at ROTH Conference on March 18th

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ImmunoCellular Therapeutics to Present at ROTH Conference on March 18th

LOS ANGELES–(BUSINESS WIRE)– ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 25th Annual ROTH Conference on Monday, March 18, 2013 at 1:30 pm PT at the Ritz-Carlton, Laguna Niguel, CA.

To access the live audio webcast of the ROTH presentation, please log on through a link located in the Investors section of ImmunoCellular’s website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.348.0010
jane@jmgcomm.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article ImmunoCellular Therapeutics to Present at ROTH Conference on March 18th originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results


Conference Call Today at 5:00 pm ET

LOS ANGELES–(BUSINESS WIRE)– ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the year and quarter ended December 31, 2012.

For the year ended December 31, 2012, the Company incurred a net loss of $14.5 million, or $0.35 per basic and diluted share compared to a net loss of $5.7 million for the year ended December 31, 2011, or $0.21 per basic and diluted share. The net loss for 2012 includes a charge of $2.3 million related to the revaluation of the Company’s warrant derivatives and $496,000 in stock-based compensation. The net loss for 2011 included a credit of $2.9 million related to the revaluation of the warrant derivatives and charge of $1.2 million for stock-based compensation.

For the quarter ended December 31, 2012, the Company reported net income of $484,000, or $0.01 per basic and diluted share, compared to a net loss of $1,499,000, or $0.05 per basic and diluted share for the quarter ended December 31, 2011. The income for the quarter ended December 31, 2012, reflects a credit of $2.7 million related to the revaluation of the Company’s warrant derivatives. The net loss for the quarter ended December 31, 2011 reflects a credit of $1.4 million related to the revaluation of the Company’s warrant derivatives.

The Company reported that cash used in operations during 2012 was $12.4 million compared to $6.4 million in 2011. The increase reflects the continued ramp-up of the company’s Phase II clinical trial of ICT-107 as well as research and development activities for ICT-121 and ICT-140. Additionally, the Company’s general and administrative expenses increased in 2012 in order to develop and support its additional infrastructure. For the quarter ended December 31, 2012, the Company’s cash used in operations was $3.2 million compared to $1.8 million in the same period of 2011.

As of December 31, 2012, the Company had $26.2 million in cash. During 2012, the Company completed two equity financings which provided $28.6 million, net of expenses, and received $3.2 million from the exercise of warrants.

With respect to the estimates regarding the interim analysis of the ongoing ICT-107 phase II clinical trial, the completion and announcement of the interim analysis by the data monitoring …read more
Source: FULL ARTICLE at DailyFinance

Science & Technology

Industry's first use of water-based paint for plastic chassis ICT equipment

Leave a comment

Fujitsu today announced the industry’s first in development of a water-based paint for use on the plastic chassis of servers, personal computers, and other ICT equipment. The new water-based paint is used on the front panels of the SPARC M10-4 and SPARC M10-4S in the SPARC M10 series of UNIX servers available in 2013. …read more
Source: FULL ARTICLE at Phys.org

Business, Finance, Occupation & Industry

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

LOS ANGELES–(BUSINESS WIRE)– ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent application covering ICT-121, an immunotherapeutic vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors. The patent includes claims covering composition of matter as well as methods of use. Specifically, the claims encompass immunogens comprising a CD133 epitope and variants thereof as well as methods of using such immunogens in immunization and to elicit cytotoxic T lymphocyte responses that are specific for tumor cells expressing HLA-A2.

“This issued patent provides significant protection for ICT-121 with what we believe are broad claims, and is an important addition to ImmunoCellular’s intellectual property estate for our cancer vaccines and monoclonal antibodies,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We believe that our growing IP asset strengthens our leadership position in the cancer immunotherapy field, and we look forward to continuing to advance our cancer immunotherapy product candidates through the development process.”

ICT-121 is a dendritic cell vaccine. CD133 is highly expressed on cancer stem cells on most solid tumors, including brain, colon, non-small cell lung, melanoma, pancreatic and breast cancers. ImmunoCellular plans to support an investigator-sponsored, 20-patient phase I trial in recurrent glioblastoma at Cedars-Sinai Medical Center.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized and the timing of the initiation of the ICT-121 phase I clinical trial. Additional risks and uncertainties are described in IMUC‘s most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as required by law, IMUC …read more
Source: FULL ARTICLE at DailyFinance

Science & Technology

Conflicts in Wikipedia now modelled by statistical physicists

Leave a comment

Information and communication technology has enabled us to solve complex problems in collaboration across the world. Everything from wiki-based platforms to open software development all the way to the experiments in CERN has benefited from advances in ICT. Not only have unprecedented forms of synergy emerged, but also inevitable clashes of opinions between large numbers of individuals. …read more
Source: FULL ARTICLE at Phys.org

News, Politics, Government

$1.6 Million Tech Incubation Program Launched In Kenya

Leave a comment

By Mfonobong Nsehe, Contributor The Kenyan government today partnered with Nailab, a Kenyan incubator, to launch a $1.6 million technology incubation program in an effort to support ’s growing information and communications technology (ICT) startup community. The Kenyan government aims to become one the top 10 ICT hubs in the world.
Source: FULL ARTICLE at Forbes Latest